FN1 and metabolic dysfunction-associated steatohepatitis: In humans, hepatic fibronectin is a predictor of fibrosis progression in obese individuals with MASH [46], and plasma fibronectin was used in a non-invasive score to predict fibrosis stage in individuals with chronic hepatitis C virus (HCV) [47].